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Background: The present phase II study aimed to assess the feasibility and efﬁcacy of a new
paclitaxel-based neoadjuvant chemoradiation regimen followed by surgery in patients with
stage II–III esophageal cancer.
Methods: From January 2002 to November 2004, 50 patients with a potentially resectable
stage II–III esophageal cancer received chemotherapy with paclitaxel, carboplatin, and 5-FU
in combination with radiotherapy 45 Gy in 25 fractions. Surgery followed 6–8 weeks after
completion of neoadjuvant treatment.
Results: Patient characteristics: male/female: 44/6, median age 60 years (34–75), median
WHO 1 (0–2), adenocarcinoma (n = 42), squamous cell carcinoma (n = 8). Toxicity was
mild, and 84 % of the patients completed the whole regimen. Forty-seven patients underwent
surgery with a curative intention (transhiatal n = 44, transthoracic n = 3).
Pathologic complete tumor regression was achieved in 18 of 47 operated patients (38%). R0
resection was achieved in 45 of 47 operated patients (96%). There were four postoperative
deaths (8.5). Postoperative complications were comparable with other studies. After a median
follow-up of 41.5 months (21–59) estimated 3- and 5-year survival on an intention-to-treat
basis was 56 and 48%. Estimated 3-year survival in responders was 61%, in nonresponders
33%.
Conclusion: This novel neoadjuvant chemoradiation regimen for treatment of patients with
stage II–III esophageal cancer is feasible. Results are encouraging with a high pathologic
complete tumor regression and R0 resection rate and an acceptable morbidity and mortality.
Preliminary survival data are very promising.
Key Words: Esophageal cancer—Neoadjuvant chemoradiation—Paclitaxel—Pathologic com-
plete response—Tumor regression grade.
The prognosis of patients with esophageal cancer
who undergo surgery with a curative intention is
poor, with a 5-year survival rate of 5–20%.
1 In recent
decades, several efforts have been made to improve
outcome. Improved and standardized surgical tech-
niques and supportive care as well as concentration of
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88care have contributed to a better outcome; however,
further improvement of survival from a single
modality approach seems unlikely.
2,3
Neoadjuvant chemoradiation has become the focus
of interest to improve long-term survival and reduce
recurrence rates. Despite a large number of phase II
and several phase III trials, the role of neoadjuvant
chemoradiation remains unclear. Until now, only one
phase III trial demonstrated a signiﬁcant survival
advantage.
4 All neoadjuvant regimens used in these
phase III trials were cisplatin-based, which leads to
frequent toxicity-related dose reductions and delays
and relatively low pathologic complete response rates
(10–28%).
New neoadjuvant chemoradiation regimens
including drugs such as paclitaxel have shown
encouraging complete response rates (29–39%) and
R0 resection rates.
5–7 Since pathologic complete
response and R0 resection have been shown to be
associated with improved survival,
8,9 it can be ex-
pected that these new regimens lead to better survival
rates. Therefore, the optimal neoadjuvant treatment
regimen with high pCR rates and minimal toxicity
has to be determined.
Paclitaxel interferes with mitotic spindle function
by enhancing the rate and yield of microtubule
assembly and preventing microtubule depolymer-
ization.
10 Paclitaxel is a potent radiosensitizer
because it synchronizes cells at G2/M, the phase of
the cell cycle that is particularly sensitive to radio-
therapy.
11,12 Furthermore, paclitaxel radiosensitiza-
tion persists well after the period of G2/M
synchronization, suggesting that other factors may
also relate to its ability to enhance radiotherapy.
13
The p53 gene is required for initiation of apoptosis
in response to most chemotherapeutic agents and
radiotherapy. In vitro, paclitaxel-mediated blockade
at the G2/M has shown to activate cell-cycle con-
trol pathways that induce apoptosis independent of
p53.
14
Therefore, paclitaxel-based neoadjuvant chemora-
diation seems a rational treatment approach for
esophageal cancer. A recent study by Meluch et al.
6
has reported an encouraging complete response rate
of 38% with a paclitaxel-based regimen. However,
toxicity was severe as only 54% of the patients
received a full dose of the neoadjuvant regimen,
because of complicating esophagitis and leucopenia.
The goal of this study was to assess the feasibility and
efﬁcacy of a new paclitaxel-based neoadjuvant
chemoradiation protocol in which we applied a re-
duced chemotherapy dose compared with the proto-
col of Meluch et al.
6
PATIENTS AND METHODS
Patients
Referral to our institute was accomplished as a
result of agreements between hospitals aﬃliated to
the Comprehensive Cancer Centre South in the
Netherlands to concentrate surgical care of patients
with esophageal cancer. The protocol of this pro-
spective clinical phase II trial was approved by the
Medical Ethics Committee, and from all patients
written informed consent was obtained. All consec-
utive patients with a potentially resectable stage II
and III esophageal cancer who were referred to our
Centre between January 2002 and November 2004
were found eligible.
Further eligibility criteria included: patient age
between 18 and 75 years, WHO performance status
£2, written informed consent, central venous cathe-
ter, and adequate hematological, renal, and hepatic
functions deﬁned as white blood cell count >
3.5 · 10
9/L, platelet count > 100 · 10
9/L, creatinine
level < 120 lmol/L and/or creatinine clearance > 60
mL/min, and normal hepatic enzyme levels. Patients
with distant metastatic disease or tumor positive
supraclavicular lymph nodes were excluded from
entry into the protocol. However, M1a disease in the
regional lymph nodes was not.
Pretreatment staging evaluation included clinical
examination, upper gastrointestinal endoscopy with
histological biopsies of the tumor, computed
tomography (CT) scan of chest and upper abdomen,
and ultrasound of the neck. Endoscopic ultrasound
(EUS) was performed when a T1 tumor could not be
excluded by conventional techniques. More recently,
PET imaging was introduced to exclude distant
metastases.
Neoadjuvant Treatment
The neoadjuvant regimen consisted of paclitaxel
175 mg/m
2 intravenously and carboplatin AUC 5
intravenously (IV) on day 1 and 22, and 5-FU 200
mg/m
2 continuous infusion on day 1–42. All patients
were treated prophylactic with dexamethasone 20 mg
and a 5HT3 antagonist IV followed by ranitidine 50
mg IV and clemastine 2 mg IV.
Radiotherapy was performed with a linear accel-
erator with a minimal photon energy of 6 MV. The
total dose of 45 Gy was given in 25 fractions of 1.8
Gy once daily, starting on day 1. The radiation ﬁelds
encompassed the primary tumor and enlarged lymph
nodes, if any, deﬁned by endoscopy, CT scan, and
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gins and a 2-cm radial margin. Neoadjuvant treat-
ment was given on a fully outpatient base.
Dose modiﬁcations were made for a toxic reaction
as deﬁned according to the criteria of the World
Health Organization (WHO).
15
Surgery
Surgery was planned 6–8 weeks after completion of
neoadjuvant treatment. For tumors in the distal third
of the esophagus, a transhiatal approach was used
whenever possible. A thransthoracic Ivor-Lewis
technique was used for tumors in the proximal and
middle third of the esophagus. Esophagogastric
continuity was reestablished using the stomach with a
cervical anastomosis in all patients. A feeding jeju-
nostomy was placed, and enteral feeding was started
24 hours after surgery.
Data Collection
The following data were prospectively collected:
age, sex, WHO performance status, location of the
tumor, histology of the tumor, comorbidity, toxicity
of neoadjuvant treatment, type of resection, and
postoperative course and complications.
Histological Examination
All pathology reports and specimens were centrally
reviewed by one pathologist (GL). Pathologic assess-
ment was performedafter standardhematoxylin-eosin
(H&E) staining. The assessment included a determi-
nation of the histological type of the tumor, the depth
of invasion of the tumor, whether there was nodal
involvement, and the status of circumferential, prox-
imal, and distal resection margins. The tumor stage
was deﬁned according to the classiﬁcation of the
American Joint Committee on Cancer.
16 Patients with
no residual viable tumor cells in the surgical specimen
were classiﬁed as having a pathologic complete re-
sponse (pCR). In addition, response after chemora-
diation of the primary tumor was classiﬁed according
to the Tumor Regression Grade (TRG) as described
by Mandard et al.
17 Categories according to the TRG
ranged from TRG1, complete regression, to TRG 5
with no regressive changes. TRG 1–3 scores were de-
fined as a major response to chemoradiation.
Statistical Analysis
The analyses were performed on the basis of
intention-to-treat. Survival time was calculated as the
duration from the day of start of chemoradiation
therapy until death or last day of follow-up, and
recurrence free interval was calculated from the day
of surgery until the day of diagnosis of recurrence.
Overall survival and disease-free survival were esti-
mated using the Kaplan-Meier method. Median
survival time was obtained from the time corre-
sponding to 50% survival based on the Kaplan-Meier
survival curve. The log-rank test was used to assess
survival diﬀerences. Signiﬁcance was deﬁned at a
conﬁdence level of P < .05. Statistical analyses were
performed with SPSS version 15.
RESULTS
Patient Characteristics
Fifty-two patients with stage II–III esophageal
carcinoma were treated in the period between Jan-
uary 2002 and November 2004. Two patients were
found ineligible. One patient had a history of
Hodgkins disease and squamous cell carcinoma of
the tongue. Previous treatment of this patient in-
cluded external beam radiotherapy on the chest. One
patient had intellectual disability (mental retarda-
tion) and was extremely anxious. Therefore, our
study population consisted of 50 patients. All 50
patients signed the written informed consent and
were included. Patient characteristics are detailed in
Table 1.
TABLE 1. Patient characteristics
No. of patients n =5 0
Age (years)
Median 60
Range 34–75
Sex
Male 44
Female 6
WHO performance status
Median 1
Range 0–2
ASA classiﬁcation
I2 4
II 24
III 2
IV –
Tumor location
Upper third 2
Middle third 1
Lower third 47
Histology
Adenocarcinoma 42
Squamous cell carcinoma 8
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Forty-two patients (84%) completed full neoadju-
vant treatment. Three patients discontinued chemo-
therapy prematurely due to grade II hand-foot
syndrome, four patients due to esophagitis, and one
due to grade IV leucopenia. Forty-seven patients
(94%) received at least 5 weeks chemotherapy; the
remaining three patients discontinued chemotherapy
in week 4. Full dose of radiotherapy was received by
49 patients (98%). Grade III leucopenia occurred in
23 patients (46%), without febrile episodes. No other
hematologic toxicity was recorded. All 50 patients
experienced esophagitis, usually mild (£ grade 2). A
total of 13 patients (26%) needed nasogastric enteral
feeding. Infection of the indwelling central venous
catheter occurred in two patients. There were no
neoadjuvant treatment related deaths. However, one
patient died of myocardial infarction 3 weeks after
completing neoadjuvant treatment.
Postoperative Complications
Surgery was performed after a median of 8.1 weeks
(range 6.0–17.9 weeks). No significant difference was
observed between responders (TRG 1–3) and nonre-
sponders (TRG 4–5) with respect to the time between
the end of chemoradiation and surgery. Two patients
showed metastatic disease at the time of surgery;
hence, 47 patients underwent surgery with a curative
intention. Transhiatal esophageal resection was per-
formed in 44 patients; a transthoracic Ivor-Lewis
resection was performed in three patients.
The postoperative course was uneventful in 23
patients (49%).There were four postoperative deaths
(8.5%). Two patients died of necrosis of the gastric
tube. One patient developed a ﬁstula between the
gastric conduit and the trachea and died of pulmon-
ary sepsis. One patient died of a progressive chylo-
thorax. Other postoperative complications included
major anastomotic leakage (n = 5), pulmonary
complications (n = 15), recurrent nerve palsy (tem-
porary n = 4, permanent n = 1), and cardiac
arrhythmias (n = 3). An overview is outlined in
Table 2.
Pathologic Response to Neoadjuvant Treatment
Pathologic complete regression in the primary tu-
mor was achieved in 18 of 47 operated patients
(38.3%). However, in two patients the primary tumor
showed complete response, but microscopic residual
tumor was detected in locoregional lymph nodes. The
ypTNM stages of the remaining patients were:
pT1N0M0 in six patients (12.8%), pT2-3N0M0 in 12
patients (25.5%), pT1-2N1M0 in four patients (8.5%),
and pT3N1M0/pT4N0-1M0 in seven patients
(14.9%). Subsequent postoperative tumor stages are
outlined in Table 3. Postoperative tumor regression
grades (TRG) scored by an independent pathologist
are outlined in Table 4. Eighteen patients (38.3%)
showed a complete tumor regression (TRG1), and 38
TABLE 2. Postoperative complications
Type of complication No. of patients (%)
Major anastomotic leakage 5 (11)
Pulmonary 15 (32)
Pneumonia 7
Emphysema 4
ARDS 1
Mediastinal infection 1
Trachea-esoph ﬁstula 1
Chylothorax 1
Recurrent nerve palsy
Permanent 1 (2)
Temporary 4 (9)
Cardiac arrhythmias 3 (6)
Wound infection 2 (4)
Diaphragmatic hernia 1 (2)
Hospital stay (days)
Median 15
Range 9–83
ICU/MCU stay (days)
Median 2
Range 2–18
Ventilation time (days)
Median 1
Range 0–9
TABLE 3. Pathological stage of patients treated with
neoadjuvant chemoradiation and surgery
Stage, ypTNM No. of patients (%)
0 18 (38.3)
I 6 (12.8)
II a 12 (25.5)
II b 4 (8.5)
III 7 (14.9)
TABLE 4. Tumor regression grade (TRG) of patients
treated with neoadjuvant chemoradiation and surgery
TRG
a No. of patients (%)
1—Absence of histologically identiﬁable
residual cancer and ﬁbrosis extending
through the different layers of the
esophageal wall
18 (38.3)
2—Presence of rare residual cancer
cells scattered through the ﬁbrosis
11 (23.4)
3—Increase in the number of residual
cancer cells, but ﬁbrosis still predominated
9 (19.1)
4—Residual cancer outgrowing ﬁbrosis 7 (14.9)
5—Absence of regressive changes 2 (4.3)
a TRG according to Mandard et al.
17
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3) after neoadjuvant treatment. Two patients had
positive margin involvement of the resected specimen;
therefore, a R0 resection was achieved in 45 of 47
patients (95.7%).
Survival and Pattern of Failure
All 50 patients were included in the survival anal-
ysis. The median follow-up for surviving patients was
41.5 months (range 21–59 months). The median
overall survival and disease-free survival were 44 and
50 months, respectively. The estimated 3- and 5-year
overall survival rates were 55.6 and 47.8%, respec-
tively, whereas the estimated 3- and 5-year disease-
free survival rates were 52.2 and 41.8%, respectively.
The Kaplan-Meier curves for overall and disease-free
survival are shown in Fig. 1 and 2.
Patients with TRG 1–3 showed a significant im-
proved overall and disease-free survival compared
with patients with TRG 4–5. Median survival time in
TRG 1–3 patients was not yet reached and 23 months
in patients with TRG 4–5. The estimated 3- and 5-
year overall survival rates were 61.0 and 55.9% for
the patients with a TRG 1–3 and 33.3 and 16.7% for
the patients with a TRG 4–5. Median disease-free
survival in TRG 1–3 patients was not yet reached and
11 months in patients with TRG 4–5. The estimated
3-year disease-free survival rates for patients with
TRG 1–3 was 58.6 vs 25.0% for patients with TRG 4–
5. Comparing the TRG 1–3 patients with TRG 4–5
patients, the log-rank test of equality of the survival
curves generated a P value of .03 for overall survival
and .02 for disease-free survival time in favor of pa-
tients with TRG1–3. The Kaplan-Meier curve for
disease-free survival according to tumor regression
grade is shown in Fig. 3.
Recurrent disease was found in 20 patients sur-
viving postoperatively (20 of 43, 47%) Five of them
were still alive at the time of the analysis. Recurrence
was only locoregional in three patients. Distant
metastases occurred in 16 patients, and in one patient
recurrence presented with locoregional and pulmon-
ary metastases.
To date 22 patients have died. Of these 22 patients,
three died from nondisease-related causes and were
presumed disease free. Of the 19 patients who had
disease-related deaths, four patients died of postop-
erative complications, and three patients died of
complications from local recurrence, whereas 12 pa-
tients died due to systemic failure that included
metastases to lung, liver, brain, and bone.
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FIG. 1. Kaplan-Meier curve of overall survival of all patients
(n = 50).
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FIG. 2. Kaplan-Meier curve of disease-free survival (n = 50).
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FIG. 3. Kaplan-Meier curve of disease-free survival by tumor
regression grade (TRG). TRG1–3 (n = 38): major response, TRG
4–5 (n = 9): minor or no response (P = .0183).
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This study shows the results of a phase II eﬃcacy
study, with a modiﬁed chemoradiation regimen
according to Meluch et al.
6 A reduction of the dose of
chemotherapy components of this regimen resulted in
a decrease of toxicity with preservation of its high
efﬁcacy rate. The pathologic complete tumor regres-
sion rate of 38.3% and R0 resection rate of 95.7 % are
among the highest described in the literature. Toxic-
ity and morbidity of this regimen compared with the
original scheme were mild and acceptable.
Numerous phase II trials using neoadjuvant
chemoradiation showed marked downstaging and
suggested survival beneﬁts. In most trials, chemo-
therapy regimens included cisplatin and 5-FU.
However, randomized controlled trials (RCT) com-
paring chemoradiation followed by surgery with
surgery alone have yielded inconclusive results.
4,18–22
One of these trials showed signiﬁcant improvement in
survival in the patients who received combined-
modality therapy.
4 The relevance of this study was
disputed because the 3-year survival rate of 6% in the
control arm was exceptionally low. Two additional
trials showed a possible beneﬁt of neoadjuvant
chemoradiation without reaching a statistical signiﬁ-
cance.
19,22 Furthermore, the power of these trials to
detect modest but clinically relevant differences was
limited by small patient numbers. In a meta-analysis
report by Fiorica et al.
23 six RCTs were pooled
comparing neoadjuvant chemoradiation and surgery
versus surgery alone. A signiﬁcant difference in 3-
year mortality favoring neoadjuvant chemoradiation
with surgery versus surgery alone was detected (OR
0.53; 95% CI 0.31–0.93; P = .03 NNT = 10). It was
concluded that neoadjuvant chemoradiation and
surgery signiﬁcantly improved 3-year survival com-
pared with surgery alone in patients with resectable
esophageal cancer. However, a careful interpretation
of these results is warranted, because this meta-
analysis was based on summarized patient data.
Neoadjuvant chemoradiation induces acute treat-
ment-related toxicity. These eﬀects include myelo-
toxicity, esophagitis, nausea, and vomiting. The
regimen used in this phase II trial produced moderate
toxicity and is comparable with reported literature on
neoadjuvant chemoradiation regimens including
paclitaxel.
5–7,24,25 The highly effective regimen used
by Meluch et al.
6 was modiﬁed to reduce toxicity. The
modiﬁcation consisted of dose reduction of 5-FU 200
mg/m
2 instead of 225 mg/m
2, paclitaxel 175 mg/m
2
instead of 200 mg/m
2 and carboplatin AUC 5.0 in-
stead of AUC 6.0. This modiﬁcation resulted in a
reduction of toxicity. Forty-two patients (84%) re-
ceived full doses of the planned 6 weeks chemother-
apy, whereas in the group of Meluch et al. only 54%
of patients received full dose chemotherapy. A rela-
tive large proportion of the patients (26%) received
preoperative nasogastric enteral feeding. This was
partly due to our liberal use of nasogastric enteral
feeding, since in our experience optimizing preoper-
ative nutritional status in patients treated with a
neoadjuvant chemoradiaton protocol is critical. The
neoadjuvant treatment was delivered on a fully out-
patient basis. Further improvement of our regimen
may be obtained by replacing 5-FU for novel oral
ﬂuoropyrimidines. In colorectal cancer, the novel
ﬂuoropyrimidines such as capecitabine and UFT
show equal if not superior efﬁcacy and improved
patient convenience.
The reported postoperative mortality in the litera-
ture for neoadjuvant chemoradiation followed by
surgery ranges from 0 to 29 % (median 9%). A
nationwide study in the United States demonstrated
in-hospital mortality rates of high-volume versus low-
volume centers of 8.4 vs 20.3%.
2 A comparative
Dutch study found in-hospital mortality rates of 4.9
vs 12.1%.
26 Therefore, the in-hospital mortality rate
of 8.5% in our trial is within these boundaries. Several
studies reported an increase in postoperative mor-
tality after neoadjuvant chemoradiation. The afore-
mentioned recent meta-analysis of six randomized
trials conﬁrmed a signiﬁcant effect of chemoradiation
on postoperative mortality (OR 2.10 95% CI 1.18–
3.73, P < .01, NNT = 25).
23 A relatively short
interval between completion of neoadjuvant therapy
and surgery of 2–4 weeks is noted in these trials and
might be of influence in the relative high mortality
rates described in these trials.
We decided to perform surgery after at least 6
weeks to achieve an adequate downstaging and per-
mit maximal recovery; in addition, surgery was
postponed in some patients due to a slow recovery
from the chemoradiation. We believe that the timing
of surgery is important. Performing an esophagec-
tomy too soon after neoadjuvant chemoradiation
may lead to increased morbidity due to prolonged
myelosuppression and hence an increased risk for
developing postoperative complications.
Until recently, neoadjuvant chemoradiation studies
have been performed using cisplatin/5-FU based
regimens with a variation in dose and a variation in
radiotherapy schemes. Moderate complete response
rates of 8–26 % and R0 resection rates of 55–84%
have been described in these studies.
4,19,20,22,27–29
With the implementation of regimens including pac-
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of 32–38% and R0 resection rates of 78–95% have
been documented.
6,7,25,30 Our study reports a com-
plete pathologic response of 38.3%, which is high.
Furthermore, a R0 resection rate of 95.7% is among
the highest described in the literature. The dismal
prognosis of esophageal cancer has discouraged
many clinicians. For many patients, the prognosis
was supposed to be dependent on the presence of
indolent distant metastasis despite the type of oper-
ative treatment given. In a recent phase III trial,
however, extended radical transthoracic esophagec-
tomy showed a trend to a better survival when
compared with a less radical transhiatal esophagec-
tomy, indicating that an adequate locoregional
treatment may have a beneﬁcial effect on survival.
3
However, in both groups a R0 resection rate of only
72% was noted. This observation is an important
rationale for neoadjuvant combined multimodality
treatment. One of the goals of neoadjuvant chemo-
radiation therapy is increasing curative R0 resection
rates by downsizing the tumor and theoretically
eradicating micrometastasis. Achieving R0 resection
in locally advanced (stage II–III) esophageal cancer
has been identified as a prognostic factor.
8,9 Fur-
thermore, complete pathologic response has been
associated with an improved survival and local con-
trol.
30,31 In the present study a major response, tumor
regression grade 1–3, resulted in a significant increase
in overall and disease-free survival. Since the time
between surgery and the end of the chemoradiation
did not significantly differ between the responders
and nonresponders, a difference in response could
not be explained by a lag-time difference. Thus, a
regimen with high complete pathologic response and
R0-resection rates will be very likely to improve
survival. However, with our relatively short follow-
up we cannot report definitive long-term survival
data yet.
In conclusion, although the discussion regarding
the value of neoadjuvant therapy is ongoing, the
neoadjuvant treatment regimens used for the last 20
years produced only modest beneﬁt, at best.
Improving chemoradiation regimens as in our study,
by incorporating modern chemotherapeutics such as
paclitaxel in combination with modern 3-D confor-
mal radiotherapy seems to be promising. Further
improvement of the systemic therapy seems to be
critical as survival is mainly determined by recur-
rences at metastatic sites. Data of ongoing phase III
trials including novel chemoradiation protocols have
to be awaited in the near future.
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